文献速递甲状腺疾病

家族性非髓样甲状腺癌罕见非编码变异的鉴定

Identification of Rare Noncoding Variants in Familial Nonmedullary Thyroid Carcinoma.
PubMed 文献 · Thyroid · 2026-01-27

该研究利用17个乳头状甲状腺癌家系的全基因组测序数据,通过自定义过滤策略筛选位于甲状腺表达调控区域的罕见非编码种系变异,共选出121个候选变异,其中56个在所有受累个体中共分离且未受累个体缺失,包括5个先前未发现蛋白编码变异的家系。结果表明非编码变异在家族性非髓样甲状腺癌病因中具有重要作用。

要点

  • 非编码种系变异可能在家族性非髓样甲状腺癌中起病因作用。
  • 采用全基因组测序与自定义过滤策略可筛选调控区候选变异。
  • 56个非编码变异与受累个体共分离,需功能研究验证致病性。

核心结论

  • 非编码变异在家族性非髓样甲状腺癌病因中重要,并提供了识别框架。

研究设计与样本

  • 基于17个乳头状甲状腺癌家系的全基因组测序数据,分析罕见非编码种系变异。
  • 采用自定义过滤策略筛选位于甲状腺表达调控区、连锁评分阳性且共分离的变异。
  • 使用BasePlayer软件进行ENCODE和转录因子结合位点注释,并分别分析表达数量性状位点、剪接数量性状位点和甲状腺增强子。

主要发现

  • 共选出121个基于计算机预测和自定义排序的候选变异。
  • 56个变异在所有受累个体中共分离且未受累个体缺失。
  • 56个变异包括5个先前未发现蛋白编码变异的家系中的候选变异。

临床怎么用

  • 对家族性非髓样甲状腺癌家系可考虑非编码区变异筛查。
  • 候选非编码变异需进一步功能验证以明确致病机制。

局限性

  • 非编码变异需进一步功能表征以理解致病分子机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Familial nonmedullary thyroid carcinoma (FNMTC) occurs when three or more family members are affected by usually papillary thyroid carcinoma (PTC), the most common form of NMTC. While the heritability to NMTC is among the highest of all cancers, the genetic determinants among NMTC families are not well understood. Here, we aim to understand the contribution of rare noncoding germline variants in the etiology of FNMTC. METHODS: We previously reported whole-genome sequencing (WGS) and linkage analysis in 17 PTC families and reported on 41 protein-coding variants in 40 genes that cosegregated with PTC in 11 of the families. Herein, we further leveraged our WGS data to include noncoding variants in our analysis for all 17 families. We hypothesized that most of the pathogenic noncoding variants would be located in theoretical or empirically determined regulatory regions that demonstrate at a minimum, basal thyroid expression, a positive family linkage score, and co-segregation among PTC-affected individuals. To test this hypothesis, we adopted a unique filtering strategy to identify variants that occurred in known DNA elements and transcription factor binding sites, near regions known to impact on gene expression or splicing in thyroid tissue, and/or in characterized thyroid enhancers. We annotated variants using two analyses (ENCODE and transcription factor binding site) within the BasePlayer software. We separately analyzed (1) expression quantitative trait loci, (2) splicing quantitative trait loci, and (3) thyroid enhancers. We then ranked variants according to predicted pathogenicity and performed Sanger sequencing in all individuals of each family. RESULTS: In total, 121 variants were selected based on in-silico prediction and our custom ranking analysis in each pedigree. Of these, 56 variants showed cosegregation among all PTC-affected individuals and were absent from unaffected individuals. This included candidate variants from five of the six PTC families for whom no protein-coding variants were previously found. CONCLUSION: Our data suggest that noncoding variants are important in the etiology of FNMTC and provide a framework for identifying noncoding germline variants using a novel approach. Further studies are needed to functionally characterize these variants to better understand the molecular mechanism of their pathogenicity.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Comiskey DF, Liyanarachchi S, Wu J, et al. Identification of Rare Noncoding Variants in Familial Nonmedullary Thyroid Carcinoma. Thyroid. 2026. PMID: 41589591. doi:10.1177/10507256251408827

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。